Aviceda Therapeutics News and Activities

Acquisition, funding and merger involving Aviceda Therapeutics.

• Aviceda Therapeutics has just announced a $208 Million fundraising (posted on January 9 2025).

View the org chart displaying its 21 main executives

Most searched biographies at Aviceda Therapeutics

• Jeffrey Nau, President, Chief Executive Officer and Director
• Emmett Cunningham, Director
• Evelyn Harrison, Director

Popular executive movements at Aviceda Therapeutics

• Diyan Patel, Senior Research Associate & Lab Manager, has left the company  (posted on April 16 2026).
• Dawn Mcneal, Clinical Trial Manager, has left the company  (posted on April 16 2026).
• Adele Fleury, Executive Administrative Assistant and Office Manager, has left the company  (posted on April 16 2026).

Create your alert
to follow the executive moves at Aviceda Therapeutics.

Aviceda Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Aviceda Therapeutics

• News and Events | Aviceda Therapeutics
• Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, in the Phase 2 SIGLEC Trial
• Aviceda Therapeutics
• Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration
• Aviceda, QUB to develop glyco-immune therapeutics
• Aviceda Therapeutics Appoints Biopharma and Business Senior Executive Patrick Johnson, PhD, to its Board of Directors
• Aviceda Therapeutics
• View more press releases Close

Social media about Aviceda Therapeutics

• Aviceda Therapeutics on Wikipedia, Google News & Yahoo Finance
• Aviceda Therapeutics on LinkedIn, X (Twitter) & YouTube